Regentis Biomaterials Ltd. (RGNT)

Regentis Biomaterials Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 29, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Debt / Equity Ratio	0.25	0.25	-	-	-	-
Net Debt / Equity Ratio	-1.30	-1.30	-	-	-	-
Net Debt / EBITDA Ratio	0.89	0.89	-	-	-	-
Net Debt / FCF Ratio	4.50	4.50	-	-	-	-
Quick Ratio	2.57	2.57	-	-	-	-
Current Ratio	2.65	2.65	-	-	-	-
Return on Equity (ROE)	-575.38%	-575.38%	-	-	-	-
Return on Assets (ROA)	-182.94%	-182.94%	-	-	-	-
Return on Invested Capital (ROIC)	969.80%	969.80%	-	-	-	-
Return on Capital Employed (ROCE)	-293.76%	-293.76%	-	-	-	-
Buyback Yield / Dilution	-249.41%	0.00%	-226.64%	-6.97%	0.00%	0.00%
Total Shareholder Return	-249.41%	0.00%	-226.64%	-6.97%	0.00%	0.00%

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: Dec 31, 2025

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

May 30, 2026

Data Sources Report a data error